WO2010072774A3 - Agent destiné au traitement de la sténose du canal rachidien - Google Patents

Agent destiné au traitement de la sténose du canal rachidien Download PDF

Info

Publication number
WO2010072774A3
WO2010072774A3 PCT/EP2009/067768 EP2009067768W WO2010072774A3 WO 2010072774 A3 WO2010072774 A3 WO 2010072774A3 EP 2009067768 W EP2009067768 W EP 2009067768W WO 2010072774 A3 WO2010072774 A3 WO 2010072774A3
Authority
WO
WIPO (PCT)
Prior art keywords
ht2a
receptor antagonists
spinal canal
ht2b receptor
treating stenosis
Prior art date
Application number
PCT/EP2009/067768
Other languages
German (de)
English (en)
Other versions
WO2010072774A2 (fr
Inventor
Rudolf Reiter
Lothar Pache
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to BRPI0923556A priority Critical patent/BRPI0923556A2/pt
Priority to CA2748163A priority patent/CA2748163A1/fr
Priority to AU2009331469A priority patent/AU2009331469A1/en
Priority to SG2011045671A priority patent/SG172315A1/en
Priority to MX2011006852A priority patent/MX2011006852A/es
Priority to CN2009801524590A priority patent/CN102271667A/zh
Priority to JP2011542819A priority patent/JP2012513446A/ja
Priority to EP09795786A priority patent/EP2367543A2/fr
Publication of WO2010072774A2 publication Critical patent/WO2010072774A2/fr
Publication of WO2010072774A3 publication Critical patent/WO2010072774A3/fr
Priority to IL213768A priority patent/IL213768A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une nouvelle utilisation de composés destinés au traitement thérapeutique ou prophylactique de patients présentant une sténose du canal rachidien, et des symptômes qui en résultent chez ces patients.
PCT/EP2009/067768 2008-12-23 2009-12-22 Agent destiné au traitement de la sténose du canal rachidien WO2010072774A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0923556A BRPI0923556A2 (pt) 2008-12-23 2009-12-22 agente para o tratamento de estenose do canal espinhal
CA2748163A CA2748163A1 (fr) 2008-12-23 2009-12-22 Agent destine au traitement de la stenose du canal rachidien
AU2009331469A AU2009331469A1 (en) 2008-12-23 2009-12-22 5-HT2A and 5-HT2B receptor antagonists for treating stenosis of the spinal canal
SG2011045671A SG172315A1 (en) 2008-12-23 2009-12-22 5-ht2a and 5-ht2b receptor antagonists for treating stenosis of the spinal canal
MX2011006852A MX2011006852A (es) 2008-12-23 2009-12-22 Agentes para el tratamiento de la estenosis del conducto vertebral.
CN2009801524590A CN102271667A (zh) 2008-12-23 2009-12-22 用于治疗椎管狭窄的5-ht2a和5-ht2b受体拮抗剂
JP2011542819A JP2012513446A (ja) 2008-12-23 2009-12-22 脊椎管狭窄症を処置するための薬剤
EP09795786A EP2367543A2 (fr) 2008-12-23 2009-12-22 Agent destiné au traitement de la sténose du canal rachidien
IL213768A IL213768A0 (en) 2008-12-23 2011-06-23 5-ht2a and 5-ht2b receptor antagonists for treating stenosis of the spinal canal

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172859 2008-12-23
EP08172859.4 2008-12-23

Publications (2)

Publication Number Publication Date
WO2010072774A2 WO2010072774A2 (fr) 2010-07-01
WO2010072774A3 true WO2010072774A3 (fr) 2010-09-23

Family

ID=40527906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/067768 WO2010072774A2 (fr) 2008-12-23 2009-12-22 Agent destiné au traitement de la sténose du canal rachidien

Country Status (11)

Country Link
EP (1) EP2367543A2 (fr)
JP (1) JP2012513446A (fr)
KR (1) KR20110098965A (fr)
CN (1) CN102271667A (fr)
AU (1) AU2009331469A1 (fr)
BR (1) BRPI0923556A2 (fr)
CA (1) CA2748163A1 (fr)
IL (1) IL213768A0 (fr)
MX (1) MX2011006852A (fr)
SG (1) SG172315A1 (fr)
WO (1) WO2010072774A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
CA3064274A1 (fr) * 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Derives d'ergoline destines a etre utilises en medecine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2229297C2 (ru) 1998-09-01 2004-05-27 Ниссан Кемикал Индастриз, Лтд. Терапевтический агент для лечения стеноза позвоночного канала
WO2004043491A1 (fr) 2002-11-14 2004-05-27 Ono Pharmaceutical Co., Ltd. Remedes contre la stenose du canal rachidien
US20070167403A1 (en) 2003-04-03 2007-07-19 Yoshifumi Takenobu Remedy for spinal canal stenosis
DE102006013307B3 (de) 2006-03-21 2007-10-04 Ergonex Pharma Gmbh Tergurid/Protergurid zur Behandlung von chronischen Schmerzen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MIHO SEKIGUCHI ET AL: "Effects of 5-HT2A receptor antagonist on blood flow in chronically compressed nerve roots", JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WOODLAND PUBLICATIONS, NEW YORK, NY, US, vol. 9, 1 January 2004 (2004-01-01), pages 263 - 269, XP007908253, ISSN: 1085-9489 *
NEWMAN-TANCREDI ADRIAN ET AL: "Differential Actions of Antiparkinson Agens at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US LNKD- DOI:10.1124/JPET.102.039883, vol. 303, no. 2, 1 November 2002 (2002-11-01), pages 815 - 822, XP008121060, ISSN: 0022-3565 *
STYCZYNSKI T: "Degenerative stenosis of lumbar spinal canal with neurogenic claudication. Pathomechanism of development of clinical symptoms and therapeutical implications", REUMATOLOGIA (WARSAW), vol. 42, no. 1, 2004, pages 59 - 63, XP008105633, ISSN: 0034-6233 *
TILO GÖRNEMANN: "Derivate von Pergolid, Lisurid und Tergurid als Liganden serotonerger, adrenerger und dopaminerger Rezeptoren", INTERNET CITATION, 2 July 2008 (2008-07-02), pages 123PP, XP007912456, Retrieved from the Internet <URL:http://www.diss.fu-berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_ derivate_000000003915/Tilo_Goernemann_Dissertation.pdf?hosts=> [retrieved on 20100330] *

Also Published As

Publication number Publication date
WO2010072774A2 (fr) 2010-07-01
MX2011006852A (es) 2011-07-20
CA2748163A1 (fr) 2010-07-01
IL213768A0 (en) 2011-07-31
CN102271667A (zh) 2011-12-07
JP2012513446A (ja) 2012-06-14
BRPI0923556A2 (pt) 2016-01-26
AU2009331469A1 (en) 2011-07-21
SG172315A1 (en) 2011-07-28
KR20110098965A (ko) 2011-09-02
EP2367543A2 (fr) 2011-09-28

Similar Documents

Publication Publication Date Title
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
SI2288372T1 (sl) IL mutein za zdravljenje ali profilakso avtoimunske bolezni
WO2011065982A3 (fr) Polymorphismes associés à la maladie de parkinson
NZ609280A (en) Method for treatment of constipation-predominant irritable bowel syndrome
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
HK1153926A1 (en) Purin derivatives for use in the treatment of fab-related diseases fab-
NZ601148A (en) Use of pentosan polysulfate for treatment or prophylaxis of allergic rhinitis
AP2011005672A0 (en) Pyrazolopyrimidines and their use for the treatment of CNS disorders.
EP2120938A4 (fr) Analogues de l&#39;imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
HK1127608A1 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MY150931A (en) Substituted oxazolidinones and their use
EP2148667A4 (fr) Utilisation de dérivés de cyclohexanehexol dans le traitement de maladies oculaires
WO2010135521A3 (fr) Compositions et procédés pour le traitement et le diagnostic de la grippe
EP2475390A4 (fr) Méthodes et compositions pour le traitement de maladies ou troubles à médiation par le récepteur tyrosine kinase
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
EP2207555A4 (fr) Nouveaux composés pour le traitement ou l&#39;atténuation des oedèmes, et leurs méthodes d&#39;utilisation
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
EP2502989A4 (fr) Composition d&#39;implant pour la régénération de tissu neural, procédé de préparation et utilisations de cette composition
MX2012000572A (es) Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980152459.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09795786

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009795786

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 593561

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2748163

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011542819

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/006852

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009331469

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4923/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009331469

Country of ref document: AU

Date of ref document: 20091222

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117017268

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011124419

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI0923556

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI0923556

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110622